Literature DB >> 10608777

Virulent Treponema pallidum, lipoprotein, and synthetic lipopeptides induce CCR5 on human monocytes and enhance their susceptibility to infection by human immunodeficiency virus type 1.

T J Sellati1, D A Wilkinson, J S Sheffield, R A Koup, J D Radolf, M V Norgard.   

Abstract

Treponema pallidum, its membrane lipoproteins, and synthetic lipoprotein analogues (lipopeptides) were each examined to determine whether they induced CCR5 expression on human peripheral blood mononuclear cells (PBMC). Reverse transcription-polymerase chain reaction for CCR5 gene transcripts, macrophage inflammatory protein (MIP)-1beta binding assays, and flow cytometry revealed that either T. pallidum, a representative treponemal lipoprotein, or a corresponding synthetic lipopeptide induced CCR5 on CD14 monocytes but not on CD3 lymphocytes. CXCR4, the coreceptor for T cell-tropic strains of human immunodeficiency virus type 1 (HIV-1), was not induced on PBMC by treponemes or by lipoproteins or lipopeptides. Consistent with these findings, T. pallidum, lipoprotein, and synthetic lipopeptide all promoted the entry of a macrophage-tropic, but not a T cell-tropic, strain of HIV-1 into monocytes. These combined results imply that T. pallidum and its constituent lipoproteins likely induce the expression of CCR5 on macrophages in syphilitic lesions, thereby enhancing transmission of macrophage-tropic HIV-1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10608777     DOI: 10.1086/315209

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  [HIV-positive patient with multiple ulcers. Lues maligna].

Authors:  A Körber; J Dissemond; U Hillen; M Goos; St Esser
Journal:  Hautarzt       Date:  2003-11       Impact factor: 0.751

2.  The effects of early syphilis on CD4 counts and HIV-1 RNA viral loads in blood and semen.

Authors:  S T Sadiq; J McSorley; A J Copas; J Bennett; S J Edwards; S Kaye; S Kirk; P French; I V D Weller
Journal:  Sex Transm Infect       Date:  2005-10       Impact factor: 3.519

Review 3.  Biological basis for syphilis.

Authors:  Rebecca E Lafond; Sheila A Lukehart
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  [Syphilis and HIV infection. Characteristic features of diagnosis, clinical assessment, and treatment].

Authors:  A Potthoff; N H Brockmeyer
Journal:  Hautarzt       Date:  2005-02       Impact factor: 0.751

5.  Lipoprotein-dependent and -independent immune responses to spirochetal infection.

Authors:  Juan C Salazar; Constance D Pope; Meagan W Moore; Jonathan Pope; Thomas G Kiely; Justin D Radolf
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

6.  Similarities in the Markers of Inflammation Between Men With Syphilis and Women With Increased Risk of HIV Acquisition.

Authors:  Noah Kojima; Claire C Bristow; Holden Maecker; Yael Rosenberg-Hasson; Segundo R Leon; Silver K Vargas; Kelika A Konda; Carlos F Caceres; Jeffrey D Klausner
Journal:  Clin Infect Dis       Date:  2015-09-22       Impact factor: 9.079

7.  Preparation of a visual protein chip for detection of IgG against Treponema pallidum.

Authors:  Yefu Wang; Wenjuan Gao; Huaquan Wang; Yihong Luo
Journal:  Mol Biotechnol       Date:  2005-10       Impact factor: 2.695

Review 8.  The role of dendritic cells in driving genital tract inflammation and HIV transmission risk: are there opportunities to intervene?

Authors:  Muki S Shey; Nigel J Garrett; Lyle R McKinnon; Jo-Ann S Passmore
Journal:  Innate Immun       Date:  2013-11-26       Impact factor: 2.680

9.  Syphilis negatively influences the response to hepatitis C virus treatment in an HIV-infected patient.

Authors:  Ellen H Nagami; Arthur Y Kim; Rachel P Baden; Barbara H McGovern
Journal:  Top Antivir Med       Date:  2012 Oct-Nov

10.  Assessment of cell-surface exposure and vaccinogenic potentials of Treponema pallidum candidate outer membrane proteins.

Authors:  Farol L Tomson; Patrick G Conley; Michael V Norgard; Kayla E Hagman
Journal:  Microbes Infect       Date:  2007-06-03       Impact factor: 2.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.